Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $19.44 and last traded at $18.14, with a volume of 663600 shares. The stock had previously closed at $18.16.
Several analysts recently issued reports on the company. BMO Capital Markets raised their target price on Halozyme Therapeutics from $15.00 to $18.00 and gave the stock a “market perform” rating in a research note on Wednesday, November 8th. Zacks Investment Research raised Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research note on Wednesday, September 27th. Barclays cut Halozyme Therapeutics from an “overweight” rating to a “hold” rating and raised their target price for the stock from $16.00 to $19.00 in a research note on Wednesday, November 22nd. BidaskClub raised Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Finally, Canaccord Genuity raised their target price on Halozyme Therapeutics from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $18.13.
The company has a current ratio of 3.46, a quick ratio of 3.37 and a debt-to-equity ratio of 2.01.
A number of institutional investors have recently bought and sold shares of HALO. Teacher Retirement System of Texas bought a new stake in Halozyme Therapeutics during the 2nd quarter valued at approximately $129,000. Arrowstreet Capital Limited Partnership bought a new stake in Halozyme Therapeutics during the 2nd quarter valued at approximately $131,000. Prudential Financial Inc. boosted its position in Halozyme Therapeutics by 8.7% during the 2nd quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 940 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Halozyme Therapeutics during the 2nd quarter valued at approximately $171,000. Finally, Amalgamated Bank boosted its position in Halozyme Therapeutics by 5.3% during the 2nd quarter. Amalgamated Bank now owns 14,067 shares of the biopharmaceutical company’s stock valued at $180,000 after acquiring an additional 705 shares in the last quarter. 84.50% of the stock is currently owned by institutional investors and hedge funds.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.